MIT biologists have designed a new peptide that can disrupt a key protein that many types of cancers, including some forms of lymphoma, leukemia, and breast cancer, need to survive.
Jan 16, 2018 in Biochemistry
A joint industry/academia study of a cancer target protein reveals unusual relation between binding site flexibility and drug-target lifetime. The results, published in Nature Communications, suggest a new strategy for drug ...
Jan 15, 2018 in Biochemistry